Pear Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019
Cash & Equivalents	48.37	169.57	112.06	29.33
Short-Term Investments	10.97	5	13.54	77.03
Cash & Cash Equivalents	59.34	174.57	125.6	106.36
Cash Growth	-66.01%	38.99%	18.09%	-
Receivables	6.94	1.79	0.26	1.01
Other Current Assets	6.68	8.88	0.2	-0.39
Total Current Assets	72.96	185.24	126.06	106.98
Property, Plant & Equipment	14.96	6.26	4.28	0.68
Long-Term Investments	0.41	0.41	0	0
Other Long-Term Assets	6.8	5.25	2.03	2.03
Total Long-Term Assets	22.17	11.92	6.31	2.71
Total Assets	95.13	197.16	132.37	109.69
Accounts Payable	3.26	1.81	4.51	2.7
Deferred Revenue	0.28	0.42	0.27	6.14
Current Debt	29.43	26.99	26.35	4.44
Other Current Liabilities	16.46	17.95	9.57	3.82
Total Current Liabilities	49.44	47.17	40.69	17.1
Long-Term Debt	9.42	0.68	0.68	10.72
Other Long-Term Liabilities	5.68	58.89	3.89	3.09
Total Long-Term Liabilities	15.1	59.56	4.56	13.81
Total Liabilities	64.54	106.73	45.25	30.91
Total Debt	38.85	27.67	27.02	15.16
Debt Growth	40.42%	2.40%	78.20%	-
Retained Earnings	-323.47	-247.98	-182.84	-69.84
Comprehensive Income	-0.05	-0	0	0.03
Shareholders' Equity	30.59	90.43	87.12	-66.04
Net Cash / Debt	20.49	146.9	98.58	91.2
Net Cash / Debt Growth	-86.05%	49.03%	8.09%	-
Net Cash Per Share	0.15	1.30	1.10	6.18
Working Capital	23.52	138.08	85.37	89.88
Book Value Per Share	0.22	0.80	0.98	-4.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).